Cell and Gene Therapies

Search documents
McKesson Bets on Oncology, Biopharma as It Streamlines Portfolio
ZACKS· 2025-10-08 16:51
Key Takeaways MCK is shifting from broad distribution to specialty-focused healthcare solutions.MCK's growth is fueled by oncology, biopharma services, automation and next-gen therapies.Medical-Surgical separation sharpens focus but poses execution and regulatory risks for MCK.McKesson (MCK) is making a strategic shift that will redefine its role in the healthcare ecosystem. Long known as one of the largest pharmaceutical distributors in North America, the company is now focusing on expanding its higher-mar ...
Dr. Park CDMO Selects Thermo Fisher Scientific to Equip New Viral Vector Manufacturing Facility
Businesswire· 2025-09-25 00:00
Sep 24, 2025 8:00 PM Eastern Daylight Time Dr. Park CDMO Selects Thermo Fisher Scientific to Equip New Viral Vector Manufacturing Facility Share Advanced bioprocessing solutions from Thermo Fisher to support large-scale production and global access to cell and gene therapies WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced that Dr. Park, an emerging viral vector contract development and manufacturing organization (CDMO) based in South Korea ...
Senti Bio to Present at the MedInvest Biotech & Pharma Conference
Globenewswire· 2025-09-18 13:15
Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [2] - The company aims to create new medicines that can precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for control even after administration [2] Upcoming Presentation - Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti, will present at the MedInvest Biotech & Pharma Conference on September 24, 2025, at 9:55 AM PT [1] - A live webcast of the presentation will be available on the company's website [2] Investor Engagement - Management will be available for one-on-one meetings with qualified members of the investor community registered for the conference [2] - The company encourages investors and the public to review information posted on its website and social media platforms regularly [3]
Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia
Globenewswire· 2025-08-12 13:15
Core Insights - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [2][4] - The company recently announced the recommended Phase 2 dose selection for its first-in-class Logic Gated off-the-shelf CAR-NK cell therapy, SENTI-202, aimed at treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML) [3] Company Overview - Senti Bio is leveraging synthetic biology to engineer Gene Circuits that enhance precision and control in new medicines, specifically targeting cancer cells while sparing healthy cells [4] - The company's pipeline includes cell therapies designed to address challenging liquid and solid tumor indications, with preclinical evidence supporting the efficacy of Gene Circuits in both NK and T cells [4] Recent Developments - The participation in the Virtual Investor segment highlights the company's ongoing efforts to communicate its advancements and strategies to potential investors [2][3] - The focus on SENTI-202 represents a significant step in Senti Bio's clinical development, indicating progress in its research and development initiatives [3]
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025
Globenewswire· 2025-08-07 12:05
Core Insights - Senti Biosciences, Inc. is advancing its clinical development of SENTI-202, having completed the dose finding phase and confirmed the recommended Phase 2 dose (RP2D) for treating relapsed/refractory AML [2][7] - The company received Orphan Drug Designation from the U.S. FDA for SENTI-202, enhancing its potential market position [7] - Senti Bio aims to grow its pipeline and expects to release additional efficacy and durability data from its ongoing Phase 1 study by the end of the year [2] Recent Pipeline and Corporate Updates - The company has completed the dose finding phase for SENTI-202 and is currently in the dose expansion phase [2][7] - Senti Bio received a $1.0 million tranche from the California Institute for Regenerative Medicine (CIRM) to support the clinical development of SENTI-202 [7] - New appointments to the leadership team include Bryan Baum to the Board of Directors and Dr. James B. Trager to the Scientific Advisory Board [7] Financial Results for Q2 2025 - As of June 30, 2025, Senti Bio reported cash and cash equivalents of approximately $21.6 million, down from $48.3 million as of December 31, 2024 [7][13] - Research and development expenses increased to $10.0 million for Q2 2025, compared to $9.2 million in Q2 2024, primarily due to higher external services and supplies costs [7][15] - General and administrative expenses rose to $6.8 million in Q2 2025 from $4.2 million in Q2 2024, mainly due to increased personnel-related expenses [7][15] - The net loss for Q2 2025 was $14.7 million, or $0.56 per share, compared to a net loss of $11.2 million in Q2 2024 [7][15][16]
MaxCyte (MXCT) Q2 Revenue Drops 18%
The Motley Fool· 2025-08-07 02:39
Core Insights - MaxCyte reported an 18% year-over-year decline in total revenue for Q2 2025, with GAAP revenue at $8.5 million, missing analyst expectations by approximately $1.1 million [1][2] - The company revised its full-year 2025 guidance, now forecasting core revenue to be flat to down 10%, a significant change from previous expectations of 8% to 15% growth [9][10] Financial Performance - GAAP net losses widened to $12.4 million, compared to the prior-year period, with EPS (GAAP) at $(0.12), a 33.3% increase in losses year-over-year [2][7] - Core revenue increased by 7.9% year-over-year to $8.2 million, despite the overall revenue decline [2][5] - Gross margin decreased from 86% in Q2 2024 to 82% in Q2 2025, reflecting lower SPL revenue [2][7] Business Operations - The installed base of ExPERT instruments grew by 12.6% to 814 units compared to Q2 2024, indicating continued adoption in the cell and gene therapy market [5] - SPL Program-related revenue fell dramatically from $2.9 million in Q2 2024 to $0.3 million in Q2 2025, with only 42% of core revenue coming from SPL clients, down from 51% [5][6] Strategic Focus - Recent strategic priorities include expanding the installed base of ExPERT instruments, signing new SPL agreements, and enhancing gene-editing safety through the SeQure Dx acquisition [4][8] - The company aims to stabilize recurring revenue and support clients in developing therapies through clinical and regulatory pathways [4] Future Outlook - Management expects SPL Program-related revenue to reach approximately $5 million for 2025, requiring significant acceleration in milestone achievements and royalties in the second half of the year [9][10] - Cash reserves stood at $165.2 million, with expectations of at least $155 million in total cash, cash equivalents, and investments by the end of 2025 [10]
Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC
Globenewswire· 2025-06-06 13:05
Core Insights - Senti Biosciences, Inc. is participating in a Virtual Fireside Chat hosted by Chardan Capital Markets on June 9, 2025, featuring key executives discussing the company's advancements in biotechnology [1][2]. Company Overview - Senti Biosciences is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3]. - The company aims to create therapies that can precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for controllability post-administration [3]. - Senti's pipeline includes cell therapies engineered with Gene Circuits targeting both liquid and solid tumors, with preclinical evidence supporting their efficacy in NK and T cells [3]. Additional Information - For further details, Senti Biosciences encourages stakeholders to visit their official website and follow their social media channels for updates and disclosures [4].
Cellectis Reports Financial Results for the First Quarter 2025
GlobeNewswire News Room· 2025-05-12 20:30
Core Insights - Cellectis reported financial results for Q1 2025, highlighting progress in clinical studies and partnerships, particularly with AstraZeneca [1][2][9] Financial Results - As of March 31, 2025, Cellectis had a cash position of $246 million, down from $264 million at the end of 2024, providing a runway into H2 2027 [10][11] - Consolidated revenues and other income for Q1 2025 were $12.0 million, an increase from $6.5 million in Q1 2024, primarily due to a $5.9 million increase in revenue recognized under the AstraZeneca joint research collaboration agreement [13][14] - R&D expenses for Q1 2025 were $21.9 million, slightly down from $22.3 million in Q1 2024, while SG&A expenses decreased to $4.7 million from $5.1 million [15][16] - The consolidated net loss attributable to shareholders was $18.1 million for Q1 2025, compared to a net income of $5.6 million in Q1 2024 [19][20] Pipeline Highlights - Cellectis is advancing its clinical programs, including the BALLI-01 study for lasme-cel (UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia, with results expected in Q3 2025 [3][6][7] - The NATHALI-01 study for eti-cel (UCART20x22) in relapsed or refractory B-cell non-Hodgkin lymphoma is ongoing, with readout expected in late 2025 [4][7] Research and Development - Cellectis presented research data on TALEN®-mediated non-viral transgene insertion and TALE base editing at the ASGCT annual meeting, showcasing advancements in gene editing technologies [5][8] - The company is focusing on the development of its pipeline, including manufacturing and clinical trial expenses for UCART22 and UCART20x22 [12] Partnerships - Ongoing R&D activities under the AstraZeneca partnership include three programs: one allogeneic CAR T for hematological malignancies, one for solid tumors, and one in vivo gene therapy for a genetic disorder [9][6]
Senti Bio to Present at the Citizens JMP Life Sciences Conference
Globenewswire· 2025-04-30 13:00
Core Insights - Senti Biosciences, Inc. announced positive preliminary clinical results for its lead program, SENTI-202, targeting Relapsed/Refractory AML [1] - The company will present these results at the Citizens JMP Life Sciences Conference on May 8, 2025, in New York [1][2] - Senti Bio is focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [3] Company Overview - Senti Bio is a clinical-stage biotechnology company dedicated to creating innovative cell and gene therapies for patients with incurable diseases [3] - The company utilizes a synthetic biology platform to engineer Gene Circuits that enhance precision and control in targeting cancer cells while sparing healthy cells [3] - Senti Bio's pipeline includes cell therapies designed to address challenging liquid and solid tumor indications, with preclinical evidence supporting the efficacy of Gene Circuits in NK and T cells [3]
Senti Bio Participates in a Virtual Investor KOL Connect Segment
Globenewswire· 2025-04-21 13:05
Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [2][4] - The company aims to create therapies that enhance precision and control in targeting cancer cells while sparing healthy cells [4] Lead Program - Senti Bio's lead program, SENTI-202, targets hematologic cancers by focusing on CD33 and/or FLT3 [4] - SENTI-202 is currently enrolling patients in a Phase I clinical trial, indicating progress in clinical development [4] Research and Development - The company has demonstrated preclinical success with its Gene Circuits in T cells, enabling selective targeting of solid tumors [4] - Senti Bio is advancing its capabilities through partnerships and exploring applications of Gene Circuits in other cell and gene therapy modalities beyond oncology [4] Industry Context - The discussion in the Virtual Investor KOL segment highlighted the current treatment landscape for acute myeloid leukemia (AML) and areas of unmet need [3] - The insights from respected leukemia researcher Stephen Strickland, MD, emphasize the significance of Senti Bio's innovative approach in addressing these unmet needs [3]